Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Coya Therapeutics, Inc.NASDAQ: COYA
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$1.21M, compared with $3.39M a year earlier. Trailing-twelve-month change in working capital was -$721.9K. Over 3 fiscal years it compounded at +72.8% a year.
Context
- Change in working capital amounted to 48.8% of revenue in FY2025, down 4.0 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly change in working capital holds near -$1.21M or moves back toward the trailing-twelve-month quarterly average of -$180.47K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 3.88M USD
- Year-over-year change
- +106.8%
- 4-year CAGR
- +51.4%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.88M | +106.8% |
| FY2024 | 2024-12-31 | 1.88M | +140.4% |
| FY2023 | 2023-12-31 | (4.64M) | -717.7% |
| FY2022 | 2022-12-31 | 751.84K | +1.7% |
| FY2021 | 2021-12-31 | 739.17K | — |
Change in Working Capital vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 change in working capital of $721.9K is the 9th largest of the 11 companies compared; the peer median is $1.1M.
- Its year-over-year change of -50.6% is the 5th highest of 11, against a peer median of -128.6%.
- Change in working capital amounts to 9.1% of revenue for COYA, versus a peer median of 27.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.87M | +67.2% | +66.6% | 11.4% | |
| LTM Mar 2026 | $16.57M | -13682.0% | — | — | |
| LTM Mar 2026 | $15.66M | +595.3% | +26.5% | — | |
| LTM Mar 2026 | $11.6M | -384.3% | — | — | |
| LTM Mar 2026 | $4.28M | -7474.4% | +29.6% | 3191.9% | |
| LTM Mar 2026 | $3.86M | +216.5% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $1.93M | -48.2% | — | 27.0% |
| LTM Mar 2026 | $1.73M | -162.8% | -44.0% | 172.9% | |
| LTM Mar 2026 | $721.9K | -50.6% | +72.8% | 9.1% | |
| LTM Mar 2026 | $469K | -263.4% | -20.7% | 6.6% | |
| LTM Mar 2026 | $301.74K | -94.4% | +140.1% | — | |
| Peer median (excluding COYA) | $1.1M | -128.6% | +28.0% | 27.0% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| Deferred Income Tax | 399.68K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 233.22K | 207.35K | 872.25K | 2.66M | 4.29M |
| Change in Working Capital | 739.17K | 751.84K | (4.64M) | 1.88M | 3.88M |
| Accounts Receivables | 0 | 0 | (7.5M) | 7.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 665.17K | 845.28K | 298.82K | 477.45K | (527.01K) |
| Other Working Capital | 74K | (93.45K) | 2.56M | (6.1M) | 4.41M |
| Other Non-Cash Items | (399.68K) | 4.02M | 543.19K | 25K | 2.29M |
| Operating Cash Flow | (3.9M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
| Capital Expenditures | (136.8K) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (525K) | (543.19K) | (25K) | 0 |
| Investing Cash Flow | (136.8K) | (525K) | (543.19K) | (25K) | (1.16M) |
| Debt Repayment | 0 | 10.47M | 0 | 0 | 0 |
| Common Stock Issued | 1.32K | 158 | 38.34M | 14M | 20.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (341.9K) | (1.11M) | 89.95K | 2.02M | 0 |
| Financing Cash Flow | (340.58K) | 9.36M | 38.43M | 16.03M | 20.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.38M) | 1.59M | 26.69M | 5.71M | 8.48M |
| Free Cash Flow | (4.04M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.